Phase 2 study of the lysine-specific demethylase 1 inhibitor bomedemstat for essential thrombocythemia

Harinder Gill, Francesca Palandri, David M. Ross, Joachim R. Göthert, Tara Cochrane, Stephen R. Larsen, Anna B. Halpern, Jake Shortt, James M. Rossetti, James Liang, Monia Marchetti, Andrew J. Wilson, Andrew J. Innes, Merit Hanna, Nicola Vianelli, William S. Stevenson, Alessandro M. Vannucchi, Maria Kleppe, Jessica Flynn, Georges Natsoulis, Claire N. Harrison, Hugh Young Rienhoff

Open source

DOI: 10.1182/bloodadvances.2025017575
Published: 2026-05-14
Container: Blood Advances
Publisher: American Society of Hematology
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2025017575,
  title = {Phase 2 study of the lysine-specific demethylase 1 inhibitor bomedemstat for essential thrombocythemia},
  author = {Harinder Gill and Francesca Palandri and David M. Ross and Joachim R. Göthert and Tara Cochrane and Stephen R. Larsen and Anna B. Halpern and Jake Shortt and James M. Rossetti and James Liang and Monia Marchetti and Andrew J. Wilson and Andrew J. Innes and Merit Hanna and Nicola Vianelli and William S. Stevenson and Alessandro M. Vannucchi and Maria Kleppe and Jessica Flynn and Georges Natsoulis and Claire N. Harrison and Hugh Young Rienhoff},
  year = {2026},
  journal = {Blood Advances},
  doi = {10.1182/bloodadvances.2025017575},
  url = {https://doi.org/10.1182/bloodadvances.2025017575}
}

RIS

TY  - JOUR
TI  - Phase 2 study of the lysine-specific demethylase 1 inhibitor bomedemstat for essential thrombocythemia
AU  - Harinder Gill
AU  - Francesca Palandri
AU  - David M. Ross
AU  - Joachim R. Göthert
AU  - Tara Cochrane
AU  - Stephen R. Larsen
AU  - Anna B. Halpern
AU  - Jake Shortt
AU  - James M. Rossetti
AU  - James Liang
AU  - Monia Marchetti
AU  - Andrew J. Wilson
AU  - Andrew J. Innes
AU  - Merit Hanna
AU  - Nicola Vianelli
AU  - William S. Stevenson
AU  - Alessandro M. Vannucchi
AU  - Maria Kleppe
AU  - Jessica Flynn
AU  - Georges Natsoulis
AU  - Claire N. Harrison
AU  - Hugh Young Rienhoff
PY  - 2026
JO  - Blood Advances
DO  - 10.1182/bloodadvances.2025017575
UR  - https://doi.org/10.1182/bloodadvances.2025017575
ER  -

APA

Gill, H., Palandri, F., Ross, D. M., Göthert, J. R., Cochrane, T., Larsen, S. R., Halpern, A. B., Shortt, J., Rossetti, J. M., Liang, J., Marchetti, M., Wilson, A. J., Innes, A. J., Hanna, M., Vianelli, N., Stevenson, W. S., Vannucchi, A. M., Kleppe, M., Flynn, J., Natsoulis, G., Harrison, C. N., & Rienhoff, H. Y. (2026). Phase 2 study of the lysine-specific demethylase 1 inhibitor bomedemstat for essential thrombocythemia. Blood Advances. https://doi.org/10.1182/bloodadvances.2025017575

Source records

crossref · retrieved 2026-09-26T07:58:17.146Z